Originally published by our sister publication Specialty Pharmacy Continuum
Ferring Pharmaceuticals announced that nadofaragene firadenovec-vncg (Adstiladrin) is now fully available across the United States for healthcare providers to prescribe for their adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non?muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.
Approved by the FDA in December 2022, nadofaragene